News Release: Changes to Essilor International (Compagnie Générale d'Optique) Board of Directors
07 Febbraio 2018 - 6:00PM
Changes to Essilor
International
(Compagnie Générale d'Optique) Board of
Directors
PDF Version of the news release
Charenton-le-Pont, France (February 7, 2018 - 6:00
p.m.) - The Board of Directors of
Essilor International (Compagnie Générale d'Optique) ("Essilor")
has announced two changes in its composition:
The members of the Board of
Directors congratulated Mrs. Fore on her new appointment and
thanked her warmly for her very important contribution to the
Board's work over the past two years.
-
Yi He, Director representing the employee
shareholders through the Valoptec Association, has also announced
that he will resign from the Essilor Board of Directors following
the end of his term as a Board director of the Valoptec
Association.
Given that the combination with
Luxottica is under way, the Essilor Board of Directors did not feel
this was an appropriate time to appoint two new members to succeed
them.
As Henrietta Fore had been
nominated to the Board of Directors of the future EssilorLuxottica,
a new female director will be nominated in the near future and that
appointment will be submitted for approval to Essilor's next
General Shareholders' Meeting.
About Essilor
Essilor International (Compagnie Générale
d'Optique) ("Essilor") is the world's leading ophthalmic optics
company. Essilor designs, manufactures and markets a wide range of
lenses to improve and protect eyesight. Its mission is to improve
lives by improving sight. To support this mission, Essilor
allocates more than €200 million to research and innovation every
year in a commitment to continuously bring new, more effective
products to market. Its flagship brands are Varilux®,
Crizal®,
Transitions®,
EyezenTM,
Xperio®, Foster
Grant®,
BolonTM and
Costa®. Essilor also
develops and markets equipment, instruments and services for
eyecare professionals.
Essilor reported consolidated revenue of more than
€7.1 billion in 2016 and employs approximately 64,000 people
worldwide. It markets its products in more than 100 countries and
has 33 plants, 490 prescription laboratories and edging facilities,
as well as five research and development centers around the world
(as of December 31, 2016). For more information, please visit
www.essilor.com.
The Essilor share trades on the Euronext Paris
market and is included in the Euro Stoxx 50 and CAC 40
indices.
Codes and symbols: ISIN: FR0000121667; Reuters:
ESSI.PA; Bloomberg: EI:FP.
CONTACTS
Investor Relations
Véronique Gillet - Sébastien Leroy
Ariel Bauer - Alex Kleban
Tel: +33 (0)1 49 77 42 16 |
Corporate Communications
Laura Viscovich
Tel: +33 (0)1 49 77 45 02 |
Media Relations
Maïlis Thiercelin
Tel: +33 (0)1 49 77 45 02 |
PDF Version of the news
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Essilor International via Globenewswire